Helix BioPharma Corp.
HBPCF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$62.63M
Close$
$-0.00
100.4% downside
Current Fair Value
100.4% downsideOvervalued by 100.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $62.63 Million |
|---|---|
| Enterprise Value | $60.15 Million |
| Earnings per Share | $-0.07 |
| Beta | -0.35 |
| Outstanding Shares | 76,378,098 |
Return
| Return on Equity | -22.62% |
|---|---|
| Return on Assets | -15.54% |
| Return on Invested Capital | -21.03% |
Valuation & Multiples
| P/E Ratio | -18.64 |
|---|---|
| PEG | 32.96 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -19.47 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Next Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$-0.08
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Helix BioPharma Corp.
7 employees
CEO: Thomas Mehrling
Helix BioPharma Corp. is a Canadian enterprise focused on immuno-oncology. The company's research and development efforts include L-DOS47, a drug candidate aimed at treating non-small cell lung cancer, and V-DOS47, which is designed to i...